Search Results - andrea+bertotti

1 Results

Sort By:

Genetic Alterations Related to Anti-EGFR Therapeutic Response

Unmet Need:Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are monoclonal antibodies, which prevent epidermal growth factor receptor (EGFR) activation. Several studies have identified alterations in KRAS and other genes...

Published: 6/27/2024 | Inventor(s): Livio Trusolino, Andrea Bertotti, Victor Velculescu, Vilmos Adleff, Eniko Papp

Keywords(s): Biomarker, Cancers, Colorectal Cancer, Disease Indication, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer